Quality systems, diabetes, and blood-typing products helped Bio-Rad keep sales nearly flat in the three months ended June 30. The company’s revenue was $651.0 million, down 0.1% from the comparable period a year earlier, while gross margin barely budged to 53.1%.
That is the ordinary reading: a stable medical-device business, with some product lines making up for weaker infectious-disease sales. The less ordinary part sits below the operating line. Net income rose 16.9% to $371.4 million, even as operating income fell 5.8% to $72.6 million.
The reason is not a sudden burst of laboratory productivity. Bio-Rad recorded a $458.0 million gain from changes in the fair value of equity securities and a loan receivable during the latest three months, compared with a $334.4 million gain in the comparable period. The investment portfolio supplied the larger swing.
Bio-Rad described the source of that volatility in its 10-Q:
"Gains and losses are primarily due to the timing of product shipments and intercompany debt payments, market volatility, and the change in the fair value of our foreign exchange contracts. (Gains) losses from change in fair market value of equity securities and loan receivable was gain of $458.0 million and $334.4 million for the second quarter of 2026 and 2025, respectively."
10-Q, Aug. 4, 2026
In plain English, the earnings increase says much more about marked-to-market assets than about the products Bio-Rad sold. That distinction matters because operating margin slipped from 11.8% to 11.2%, while net margin climbed from 48.8% to 57.1%.
The business itself had a narrower, more workmanlike explanation. On a currency-neutral basis, sales increased 0.3%, with growth in quality systems, diabetes, and blood typing products partly offset by lower infectious-disease sales. The company also said the academic research market remained difficult, particularly in the Americas.
The cost line added another complication. Bio-Rad said foreign-exchange effects from a weaker U.S. dollar increased selling, general, and administrative expense, with lower restructuring costs partly offsetting that pressure.
"The increase in SG&A expense was primarily due to foreign exchange impact resulting from a weaker U.S. dollar on our international cost base, partially offset by lower restructuring costs."
10-Q, Aug. 4, 2026
So the latest report contains two different businesses in miniature: a product operation with essentially no reported sales growth and lower operating profit, and an investment book that generated a large accounting gain. Cash rose 40.0% to $517.0 million, but Bio-Rad attributed the change primarily to the timing of purchases, maturities, and sales of marketable securities and investments, partly offset by the Stilla acquisition outflow in the comparable period.
That investment exposure is not entirely abstract. Bio-Rad’s filing also says changes in the market value of Sartorius ordinary shares affect value appreciation rights tied to a loan. It is a reminder that reported net income can move with assets outside the company’s core product demand.
The unresolved point is operational: Bio-Rad’s latest filing says why SG&A rose and which product groups moved, but it does not say whether the 0.3% currency-neutral sales increase can offset the academic research weakness and the lower operating margin. Bio-Rad’s next quarterly report leaves one specific question on the table: what happens to operating income when the investment line is not doing the heavy lifting?
Bio-Rad’s Aug. 4, 2026 10-Q reported $651.0 million of revenue, $72.6 million of operating income, and a $458.0 million gain from equity securities and a loan receivable.